Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

Lantern Pharma, an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (“ML”) platform with multiple clinical stage drug programs, announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-184, which is being developed for multiple advanced solid tumors and central nervous system (CNS) cancers. The first-in-human Phase 1A trial for LP-184 is anticipated to launch and dose its first patient during the current quarter.

Read More : Salesforce Unveils Marketing GPT and Commerce GPT to Personalize Every Campaign and Shopping Experience with Generative AI

“The clearance of the IND application is a significant milestone for our LP-184 program and validates our approach of leveraging AI and machine learning to advance our pipeline of novel drug candidates,” stated Panna Sharma, Lantern’s CEO and President. “Insights from our AI platform RADR^® were instrumental in our development of LP-184 and aided in discovering its mechanism of action, identifying and prioritizing its cancer indications, and generating machine learning biomarker signatures to assist with future clinical trial patient selection. We believe LP-184 has blockbuster potential for patients with multiple types of advanced solid tumors and CNS cancers, many of which have no or limited effective therapeutic options,” continued Sharma.

AiThority: The 3 Building Blocks to Make AI Accessible

LP-184 is the first of Lantern’s drug candidates to be developed entirely internally, with the assistance of Lantern’s AI and ML platform RADR^®, to advance to a first-in-human Phase 1A trial. The Phase 1A trial will assess the safety and tolerability of escalating doses of LP-184 to determine the maximum tolerated dose (MTD) in patients with advanced pancreatic cancer, recurrent high-grade gliomas/glioblastoma (GBM), metastatic brain and CNS cancers, and other solid tumors with DNA damage response (DDR) deficiencies. Lantern anticipates the Phase 1A trial to be completed by the first half of 2024.

After the Phase 1A trial is completed, Lantern will advance LP-184 into additional clinical trials for multiple solid tumor indications, and Lantern’s subsidiary, Starlight Therapeutics, will advance the clinical development of LP-184 for all brain and CNS indications under the name STAR-001. Globally, the aggregate annual market potential of LP-184/STAR-001’s programs is estimated to be approximately $11-13 billion, consisting of $6-7 billion for solid tumors and $5-6 billion for CNS cancers.